Table 4.
Clinical trials evaluating WEE1/PKMYT1 inhibitor in monotherapy or in combination for cancer therapy
| Study ID | Study title | Tumor | Interventions | Status | Phase |
|---|---|---|---|---|---|
| NCT02610075 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | S | AZD1775 | C | 1 |
| NCT03668340 | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma | S | AZD1775 | R | 2 |
| NCT02482311 | Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | S | AZD 1775 | C | 1 |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | S | AZD1775 | NA | 1 |
| NCT03315091 | Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours | S | AZD1775 | C | 1 |
| NCT01748825 | AZD1775 for Advanced Solid Tumors | S/H | AZD1775 | ANR | 1 |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | S | AZD1775 + Olaparib | C | 1 |
| NCT03313557 | AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies | S | AZD1775 | C | 1 |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | S | AZD1775 | NA | 2 |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation | S | AZD1775 | T | 2 |
| NCT02087176 | A Placebo Controlled Study Comparing AZD1775 + Docetaxel Versus Placebo + Docetaxel to Treat Lung Cancer | S | AZD1775 + Docetaxel | T | 2 |
| NCT03012477 | CISPLATIN + AZD-1775 In Breast Cancer | S | AZD1775 + Cisplatin | ANR | 2 |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | S | AZD1775 + Carboplatin or Paclitaxel | C | 1 |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | H | AZD1775 + Cytarabine or Filgrastim or Fludarabine Phosphate | W | 1 |
| NCT02513563 | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | S | AZD1775 + Carboplatin or Paclitaxel | R | 2 |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | H | AZD1775 + Cytarabine | T | 2 |
| NCT02585973 | Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | S | AZD1775 + Cisplatin + Radiation | R | 1 |
| NCT02087241 | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | S | AZD1775 + pemetrexed or carboplatin | T | 2 |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | H | AZD1775 + Belinostat | T | 1 |
| NCT03333824 | Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer | S | AZD1775 | C | 1 |
| NCT02906059 | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | S | AZD1775 + Irinotecan | R | 1 |
| NCT02037230 | Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | S | AZD1775 + Gemcitabine+ Radiation Therapy | C | 1,2 |
| NCT02617277 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | S | AZD1775 + Durvalumab | ANR | 1 |
| NCT02666950 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | H | AZD1775 + Cytarabine | C | 2 |
| NCT01047007 | A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005) | S | AZD1775 + 5-FU or 5-FU/CDDP | T | 1 |
| NCT01164995 | Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer | S | AZD1775 + carboplatin | NA | 2 |
| NCT02448329 | Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | S | AZD1775 + paclitaxel | R | 2 |
| NCT02508246 | WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | S | AZD1775 + Cisplatin + Docetaxel | C | 1 |
| NCT03253679 | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification | S | AZD1775 | R | 2 |
| NCT01076400 | A Study of MK-1775 in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | S | AZD1775 + Topotecan or Cisplatin | T | 1,2 |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | S | AZD1775 +Cisplatin | T | 2 |
| NCT02101775 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | S | AZD1775 + Gemcitabine | ANR | 2 |
| NCT03028766 | WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer | S | AZD1775 + Cisplatin + Radio therapy | ANR | 1 |
| NCT01357161 | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | S | AZD1775 + paclitaxel + carboplation | C | 2 |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | S | AZD1775 | R | 2 |
| NCT00648648 | A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) | S | AZD1775 + Gemcitabine or Cisplatin or Carboplatin | C | 1 |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | S | AZD-1775 + Gemcitabine + paclitaxel | ANR | 1,2 |
| NCT02576444 | Olaparib Combinations | S | AZD1775 + olaparib | ANR | 2 |
| NCT04197713 | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study | S | AZD1775 + olaparib | ANR | 1 |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | S | AZD1775 + Radiation Therapy | ANR | 1 |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | S | AZD1775 + olaparib | R | 2 |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | S | AZD1775 + Irinotecan or Irinotecan Hydrochloride | R | 1,2 |
| NCT03345784 | Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer | S | AZD1775 +Cisplatin + Radiation (External Beam Radiation Therapy) | R | 1 |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | S | AZD1775 + Radiation Therapy + Temozolomide | R | 1 |
| NCT02937818 | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | S | AZD1775 + carboplatin | ANR | 2 |
| NCT02546661 | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | S | AZD1775 + Durvalumab | ANR | 1 |
| NCT02659241 | Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | S | AZD1775 | R | 1 |
| NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | S | AZD1775 + Paclitaxel or Carboplatin or Gemcitabine or pegylated liposomal doxorubicin | ANR | 2 |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | S/H | AZD1775 + carboplatin | R | 1,2 |
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | S | AZD1775 + olaparib | R | 2 |
| NCT01827384 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | S | AZD1775 + carboplatin | R | 2 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | S/H | AZD1775 | R | 2 |
S solid tumor, H hematological tumor, C completed, R recruiting, W withdraw, ANR active not recruiting, T terminated, NA status unknown (last update 04/22/2020)